Quantcast

Latest rheumatoid arthritis Stories

2014-10-17 23:02:09

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled persons may be using Enbrel that, based on the manufacturer’s own guidelines, should not be used and should be discarded immediately; the plaintiff further alleges that the unapproved Enbrel is ineffective in treating his arthritis...

2014-10-13 08:27:39

- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-10-13 08:27:34

Be Joint Smart to educate roughly 28,000 local residents with PsA about their disease PORTLAND, Ore., Oct. 13, 2014 /PRNewswire-USNewswire/ -- If you're one of the roughly 28,000 Seattle metro residents struggling with pain from psoriatic arthritis (PsA)--an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons--learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at...

2014-10-08 16:23:50

Be Joint Smart to educate roughly 23,200 local residents with PsA about their disease PORTLAND, Ore., Oct. 8, 2014 /PRNewswire-USNewswire/ -- If you're one of the roughly 23,200 San Diego metro residents struggling with pain from psoriatic arthritis (PsA)--an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons--learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation,...

2014-10-08 12:28:53

Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that despite the increasing percentage of rheumatoid arthritis (RA) patients treated with agents with a newer mechanism of action (MOA), three-quarters of DMARD-failure RA patients who are naive to biologics/Pfizer's Xeljanz are still initiated on tumor necrosis...

2014-10-07 12:28:28

Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed rheumatologists in France, Germany and the United States expect to prescribe biosimilar infliximab within one year of launch if the biosimilar is priced at a net discount of 15-30 percent to Remicade and has demonstrated...

2014-10-06 12:28:55

Medac Pharma Brings Rasuvo From U.S. Concept to Launch in One Year ­­CHICAGO, Oct. 6, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo(TM) (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. Rasuvo is a single dose, subcutaneous methotrexate (MTX) auto injector offering the widest dose range in a...

2014-10-06 08:28:13

-- Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 percent of all JIA patients NORTH CHICAGO, Ill., Oct. 6, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. HUMIRA was approved in the United States in 2008 for...

2014-10-05 23:01:42

Non-profit arthritis support group CreakyJoints addresses underserved housekeeping needs of those with arthritis and rheumatic disease with new “Clean My House” monthly member drawing. Upper Nyack, NY (PRWEB) October 05, 2014 CreakyJoints (http://www.creakyjoints.org), a non-profit arthritis education and advocacy organization with an online community of more than 73,000 people, has added an unprecedented new membership benefit: “Clean My House,” a monthly drawing to send a...

2014-10-01 16:27:17

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel(®) (etanercept) and ABP 501 (adalimumab biosimilar) at the 23(rd) Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related